Begriffe & Kennungen
Begriff oder HOS-ID gezielt finden. Die alphabetische Liste können Sie seitenweise durchblättern.
121.705 Begriffe
Apixaban Accord · 4.5 · Inducers of CYP3A4 and P-gp Coadministration of apixaban with rifampicin, a strong inducer of both CYP3A4 and
HOS-146624Apixaban Accord · 4.5 · Inhibitors of CYP3A4 and P-gp Coadministration of apixaban with ketoconazole (400 mg once a day), a strong inh
HOS-146618Apixaban Accord · 4.5 · Inhibitors of CYP3A4 and P-gp Coadministration of apixaban with ketoconazole (400 mg once a day), a strong inh
HOS-146671Apixaban Accord · 4.5 · Interaction studies have not been performed in paediatrics.
HOS-146650Apixaban Accord · 4.5 · Interaction studies have not been performed in paediatrics. The above mentioned interaction data was obtained
HOS-146691Apixaban Accord · 4.5 · Naproxen (500 mg), an inhibitor of P-gp, led to a 1.5-fold and 1.6-fold increase in mean apixaban AUC and Cmax
HOS-146632Apixaban Accord · 4.5 · Naproxen (500 mg), an inhibitor of P-gp, led to a 1.5-fold and 1.6-fold increase in mean apixaban AUC and Cmax
HOS-146679Apixaban Accord · 4.5 · Naproxen Coadministration of single doses of apixaban (10 mg) and naproxen (500 mg), a commonly used NSAID, di
HOS-146687Apixaban Accord · 4.5 · Naproxen Coadministration of single doses of apixaban (10 mg) and naproxen (500 mg), a commonly used NSAID, di
HOS-146645Apixaban Accord · 4.5 · Other concomitant therapies No clinically significant pharmacokinetic or pharmacodynamic interactions were obs
HOS-146683Apixaban Accord · 4.5 · Other concomitant therapies No clinically significant pharmacokinetic or pharmacodynamic interactions were obs
HOS-146639Apixaban Accord · 4.5 · Paediatric population
HOS-146649Apixaban Accord · 4.5 · Paediatric population
HOS-146690Apixaban Accord · 4.5 · Pharmacokinetic or pharmacodynamic interactions were not evident when apixaban was coadministered with ASA 325
HOS-146677Apixaban Accord · 4.5 · Pharmacokinetic or pharmacodynamic interactions were not evident when apixaban was coadministered with ASA 325
HOS-146628Apixaban Accord · 4.5 · The above mentioned interaction data was obtained in adults and the warnings in section 4.4 should be taken in
HOS-146651Apixaban Accord · 4.5 · The use of apixaban is not recommended in patients receiving concomitant systemic treatment with strong inhibi
HOS-146672Apixaban Accord · 4.5 · The use of apixaban is not recommended in patients receiving concomitant systemic treatment with strong inhibi
HOS-146619Apixaban Accord · 4.5 · There is limited experience of co-administration with other platelet aggregation inhibitors (such as GPIIb/III
HOS-146634Apixaban Accord · 4.5 · There is limited experience of co-administration with other platelet aggregation inhibitors (such as GPIIb/III
HOS-146681Apixaban Accord · 4.6 Fertility, pregnancy and lactation · 1
HOS-099548Apixaban Accord · 4.6 Fertility, pregnancy and lactation · 2
HOS-099554Apixaban Accord · 4.8 Undesirable effects · 1
HOS-099549Apixaban Accord · 4.8 Undesirable effects · 2
HOS-099555Apixaban Accord · 4.8 · 13 In the VTEt studies, the overall incidence of adverse reactions related to bleeding with apixaban was 15.6%
HOS-146656Apixaban Accord · 4.8 · 14 System organ class Prevention of Prevention of Treatment of Treatment of VTE in adult stroke and DVT and PE
HOS-146660Apixaban Accord · 4.8 · 15 System organ class Prevention of Prevention of Treatment of Treatment of VTE in adult stroke and DVT and PE
HOS-146661Apixaban Accord · 4.8 · 16 Reporting of suspected adverse reactions
HOS-146668Apixaban Accord · 4.8 · 46 System organ class Prevention of stroke and Treatment of Treatment of systemic embolism in adult DVT and PE
HOS-146701Apixaban Accord · 4.8 · 47 System organ class Prevention of stroke and Treatment of Treatment of systemic embolism in adult DVT and PE
HOS-146703